Literature DB >> 24916697

Cisplatin-induced renal injury is independently mediated by OCT2 and p53.

Jason A Sprowl1, Cynthia S Lancaster1, Navjotsingh Pabla1, Edwin Hermann2, Ashley M Kosloske1, Alice A Gibson1, Lie Li1, Dorothea Zeeh3, Eberhard Schlatter3, Laura J Janke4, Giuliano Ciarimboli3, Alex Sparreboom5.   

Abstract

PURPOSE: Tubular secretion of cisplatin is abolished in mice deficient for the organic cation transporters Oct1 and Oct2 (Oct1/2(-/-)mice), and these animals are protected from severe cisplatin-induced kidney damage. Since tubular necrosis is not completely absent in Oct1/2(-/-)mice, we hypothesized that alternate pathways are involved in the observed injury. EXPERIMENTAL
DESIGN: Studies were done in wild-type, Oct1/2(-/-), or p53-deficient animals, all on an FVB background, receiving cisplatin intraperitoneally at 15 mg/kg. Cisplatin metabolites were analyzed using mass spectrometry, and gene expression was assessed using Affymetrix microarrays and RT-PCR arrays.
RESULTS: KEGG pathway analyses on kidneys from mice exposed to cisplatin revealed that the most significantly altered genes were associated with the p53 signaling network, including Cdnk1a and Mdm2, in both wild-type (P = 2.40 × 10(-11)) and Oct1/2(-/-)mice (P = 1.92 × 10(-8)). This was confirmed by demonstrating that homozygosity for a p53-null allele partially reduced renal tubular damage, whereas loss of p53 in Oct1/2(-/-)mice (p53(-/-)/Oct1/2(-/-)) completely abolished nephrotoxicity. We found that pifithrin-α, an inhibitor of p53-dependent transcriptional activation, inhibits Oct2 and can mimic the lack of nephrotoxicity observed in p53(-/-)/Oct1/2(-/-)mice.
CONCLUSIONS: These findings indicate that (i) the p53 pathway plays a crucial role in the kidney in response to cisplatin treatment and (ii) clinical exploration of OCT2 inhibitors may not lead to complete nephroprotection unless the p53 pathway is simultaneously antagonized. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916697      PMCID: PMC4119572          DOI: 10.1158/1078-0432.CCR-14-0319

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria.

Authors:  N A G Santos; C S Catão; N M Martins; C Curti; M L P Bianchi; A C Santos
Journal:  Arch Toxicol       Date:  2007-01-11       Impact factor: 5.153

3.  A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.

Authors:  Kristin D Ivy; Jack H Kaplan
Journal:  Mol Pharmacol       Date:  2013-03-29       Impact factor: 4.436

4.  Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.

Authors:  Atsushi Yonezawa; Satohiro Masuda; Kumiko Nishihara; Ikuko Yano; Toshiya Katsura; Ken-ichi Inui
Journal:  Biochem Pharmacol       Date:  2005-10-20       Impact factor: 5.858

5.  Organic cation transporters are determinants of oxaliplatin cytotoxicity.

Authors:  Shuzhong Zhang; Katherine S Lovejoy; James E Shima; Leah L Lagpacan; Yan Shu; Anna Lapuk; Ying Chen; Takafumi Komori; Joe W Gray; Xin Chen; Stephen J Lippard; Kathleen M Giacomini
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.

Authors:  Michael S Christodoulou; Francesco Colombo; Daniele Passarella; Gabriella Ieronimo; Valentina Zuco; Michelandrea De Cesare; Franco Zunino
Journal:  Bioorg Med Chem       Date:  2011-01-25       Impact factor: 3.641

7.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

Authors:  P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov
Journal:  Science       Date:  1999-09-10       Impact factor: 47.728

Review 8.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

Authors:  N Pabla; Z Dong
Journal:  Kidney Int       Date:  2008-02-13       Impact factor: 10.612

9.  Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.

Authors:  Kazufumi Iwata; Keiji Aizawa; Saori Kamitsu; Sachiko Jingami; Eiko Fukunaga; Minoru Yoshida; Misato Yoshimura; Akinobu Hamada; Hideyuki Saito
Journal:  Clin Exp Nephrol       Date:  2012-05-09       Impact factor: 2.801

10.  Interaction of Cisplatin with the human organic cation transporter 2.

Authors:  Kelly K Filipski; Walter J Loos; Jaap Verweij; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

View more
  30 in total

Review 1.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

2.  Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.

Authors:  Navjotsingh Pabla; Alice A Gibson; Mike Buege; Su Sien Ong; Lie Li; Shuiying Hu; Guoqing Du; Jason A Sprowl; Aksana Vasilyeva; Laura J Janke; Eberhard Schlatter; Taosheng Chen; Giuliano Ciarimboli; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

3.  Recapitulating kidney development in vitro by priming and differentiating mouse embryonic stem cells in monolayers.

Authors:  Theresa Chow; Frances T M Wong; Claudio Monetti; Andras Nagy; Brian Cox; Ian M Rogers
Journal:  NPJ Regen Med       Date:  2020-04-20

4.  Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.

Authors:  Matthew R Trendowski; Omar El-Charif; Mark J Ratain; Patrick Monahan; Zepeng Mu; Heather E Wheeler; Paul C Dinh; Darren R Feldman; Shirin Ardeshir-Rouhani-Fard; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Robyn Hannigan; Frederick Strathmann; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2019-07-11       Impact factor: 12.531

5.  Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Authors:  Ramindhu Galgamuwa; Kristine Hardy; Jane E Dahlstrom; Anneke C Blackburn; Elize Wium; Melissa Rooke; Jean Y Cappello; Padmaja Tummala; Hardip R Patel; Aaron Chuah; Luyang Tian; Linda McMorrow; Philip G Board; Angelo Theodoratos
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

Review 6.  Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.

Authors:  Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2018-10-10       Impact factor: 12.531

Review 7.  The multifaceted role of the renal microvasculature during acute kidney injury.

Authors:  Katherine Maringer; Sunder Sims-Lucas
Journal:  Pediatr Nephrol       Date:  2015-10-22       Impact factor: 3.714

Review 8.  Role of SLC transporters in toxicity induced by anticancer drugs.

Authors:  Kevin M Huang; Muhammad Erfan Uddin; Duncan DiGiacomo; Maryam B Lustberg; Shuiying Hu; Alex Sparreboom
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-26       Impact factor: 4.481

9.  Association of Urine Platinum With Acute Kidney Injury in Children Treated With Cisplatin for Cancer.

Authors:  Asaf Lebel; Hayton Chui; Kelly R McMahon; Yong Jin Lim; Joseph Macri; Stella Wang; Prasad Devarajan; Tom D Blydt-Hansen; Michael Zappitelli; Bradley L Urquhart
Journal:  J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.126

10.  Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.

Authors:  Eman Ghonaim; Sahar El-Haggar; Suzy Gohar
Journal:  Med Oncol       Date:  2021-08-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.